A 28-year-old nulliparous woman attends the family planning clinic seeking long-acting reversible contraception. She has a regular 28-day menstrual cycle with moderate menorrhagia (60 mL blood loss per cycle) and dysmenorrhea managed with NSAIDs. She has no history of pelvic inflammatory disease, ectopic pregnancy, or sexually transmitted infections. On examination, her uterus is anteverted, normal size, and mobile. She declines hormonal contraception due to concerns about systemic side effects. Which IUCD is the most appropriate choice for this patient?

Explanation

## Clinical Assessment This patient presents with: - Nulliparity (no prior pregnancies) - Menorrhagia with dysmenorrhea (managed with NSAIDs) - **Explicit refusal of hormonal contraception** due to concerns about systemic side effects - No contraindications to IUCD insertion - Desire for long-acting reversible contraception (LARC) ## Why Copper T 380A (CuT380A) is the Most Appropriate Choice **Key Point:** The patient has explicitly declined hormonal contraception. Both the LNG-IUS (Option C) and the progesterone-releasing IUCD (Option B) are hormonal devices and must be excluded based on the patient's stated preference. Among non-hormonal IUCDs, **Copper T 380A is the gold standard** — it is the most effective, most widely used, and longest-lasting copper IUCD available (WHO Medical Eligibility Criteria, 2015; Dutta's Textbook of Gynecology). **High-Yield:** CuT380A has a Pearl Index of ~0.8 per 100 woman-years and provides contraceptive protection for up to **10 years**, making it the preferred long-acting non-hormonal IUCD. It is acceptable for nulliparous women and has no systemic hormonal effects. **Clinical Pearl:** Although copper IUCDs can increase menstrual blood loss and worsen dysmenorrhea in some users, this is a relative concern — not an absolute contraindication. The patient is already managing dysmenorrhea with NSAIDs, and her menorrhagia (60 mL/cycle) is at the lower threshold of clinical significance. Her explicit refusal of hormonal methods takes precedence in clinical decision-making. ## Why Other Options Are Incorrect | Option | Reason Excluded | |--------|----------------| | **Cu7 (Copper 7)** | Older, less effective device (Pearl Index ~1.4); largely obsolete in modern practice; inferior to CuT380A in efficacy and duration | | **Progesterone-releasing IUCD** | Hormonal device — patient declined hormonal contraception; also requires annual replacement | | **LNG-IUS (Mirena)** | Hormonal device (levonorgestrel) — patient explicitly declined hormonal contraception; cannot override patient autonomy based on "local vs. systemic" distinction in an exam context | ## Comparison of Non-Hormonal IUCD Options | Feature | CuT380A | Cu7 | |---------|---------|-----| | **Efficacy (Pearl Index)** | 0.8 | 1.4 | | **Duration** | 10 years | 5 years | | **Modern use** | First-line | Largely obsolete | | **WHO recommendation** | Yes | Not preferred | ## Insertion Considerations for Nulliparous Women **Clinical Pearl:** Nulliparity is NOT a contraindication to IUCD insertion. Modern evidence (ACOG, WHO) supports IUCD use in nulliparous women. Insertion may be slightly more uncomfortable but is safe and does not impair future fertility. Pre-medication with ibuprofen 400 mg 30 minutes before insertion is recommended. **Reference:** Dutta's Textbook of Gynecology, 9th edition; WHO Medical Eligibility Criteria for Contraceptive Use, 5th edition (2015).